🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Randomized Study of Triple Therapy vs Sildenafil Dose Optimization in Pulmonary Arterial Hypertension

RecruitingPhase 4Ages 18 Years - anyAllUniversity of Sao Paulo General Hospital
NCT07713914 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Pulmonary arterial hypertension (PAH) is a rare and progressive disease characterized by increased pressure in the pulmonary arteries, leading to right heart failure and premature death. Although combination therapy has improved outcomes, many patients remain at intermediate or high clinical risk despite treatment. When patients do not reach low-risk status, treatment escalation is recommended. However, different escalation strategies are used in clinical practice, including increasing the dose of existing medications or adding a third drug that targets a different biological pathway. There is limited prospective randomized evidence directly comparing these approaches. The ASCEND-PAH study is a prospective, randomized, open-label clinical trial designed to compare two therapeutic escalation strategies in adults with PAH who remain at intermediate or high risk despite dual therapy with

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥18 years * Diagnosis of pulmonary arterial hypertension (PAH, Group 1) confirmed according to accepted clinical and hemodynamic criteria * Stable treatment with an endothelin receptor antagonist in combination with sildenafil prior to randomization * Classified as intermediate-low, intermediate-high, or high risk according to the COMPERA 2.0 four-stratum model * Clinical indication for therapeutic escalation * Availability for follow-up assessment between 3 and 6 months after randomization * Ability to provide written informed consent Exclusion Criteria: * Participation in another interventional clinical trial that mandates treatment modification * Known contraindication to prostacyclin pathway agents (including iloprost or selexipag) * Known contraindication to sildenafil dose escalation * Pregnancy or breastfeeding * Women of childbearing potential not using effective contraception * Any clinical condition that, in the investigator's judgment, would interfere with study participation or outcome assessment
💊

What it tests

  • Prostacyclin Pathway Agent
  • Sildenafil Dose Optimization
📍

Where

1 site
Instituto do Coração (InCor), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo
São Paulo, Brazil
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy